Methoxsalen Macopharma

Methoxsalen, the active ingredient in Methoxsalen Macopharma, is a psoralen (furanocoumarin) presented as a formulation for extracorporeal use. It is employed in photochemotherapy to treat skin conditions such as psoriasis and vitiligo in adult patients.

GNH USA supplies Methoxsalen Macopharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methoxsalen is used in photochemotherapy for disorders that respond to UVA‑activated psoralen treatment.

Psoriasis: reduces scaling and plaque formation. Vitiligo: promotes repigmentation of depigmented skin. Other photodermatoses: used as part of PUVA therapy for conditions such as cutaneous T‑cell lymphoma.

Methoxsalen may cause a range of adverse reactions, some of which are dose‑related or dependent on UVA exposure.

Common Side Effects: - Nausea or gastrointestinal discomfort. - Headache or dizziness. - Transient erythema or skin redness. - Itching or mild skin irritation.

Serious or Rare Side Effects: - Severe sunburn or blistering of treated skin. - Ocular toxicity, including cataract formation. - Bone marrow suppression leading to cytopenias. - Anaphylactic or severe allergic reactions. - Increased risk of long‑term skin malignancies. - Phototoxic reactions extending beyond the treatment area.

When using methoxsalen, several safety measures should be observed to minimize risk.

Assess liver function before initiation: methoxsalen is metabolized hepatically. Avoid excessive sun exposure: protect untreated skin from UVA. Monitor complete blood count: watch for bone marrow effects. Use protective eyewear during UVA exposure: reduce risk of ocular toxicity. Contraindicated in patients with porphyria or known hypersensitivity to psoralens. Store at room temperature: keep in original container, protect from moisture and light.

Methoxsalen can interact with other medications, altering efficacy or safety.

Major Interactions (Avoid): - Azathioprine: additive immunosuppression may increase infection risk. - Cyclosporine: combined phototoxicity can exacerbate skin reactions. - Oral retinoids (e.g., acitretin): heightened risk of severe cutaneous adverse events.

Moderate Interactions (Monitor Closely): - NSAIDs: may increase photosensitivity. - Antihistamines: can mask early signs of phototoxic reactions. - Oral contraceptives: potential alteration of hormone‑related skin responses. - Antifungal agents (e.g., fluconazole): may affect methoxsalen metabolism.